Dr. Vera DePalo, FCCP, comments: This large, industry-sponsored trial provides an alternative to the standard treatments for VTE. Patients had a less likelihood of hospitalization for recurrence or major bleeding. If hospitalization did occur, there was a much longer median time to hospitalization and a shorter hospital length of stay.
The AMPLIFY trial was sponsored by Bristol-Myers Squibb and Pfizer. Dr. Johnson reported having no financial conflicts.
